O	0	3	The
O	4	10	Living
O	11	15	Well
O	16	21	after
O	22	28	Breast
O	29	35	Cancer
O	35	36	™
O	37	42	Pilot
O	43	48	Trial
O	48	49	:
O	50	51	a
B-intervention	52	58	weight
I-intervention	59	63	loss
I-intervention	64	76	intervention
O	77	80	for
O	81	86	women
O	87	96	following
O	97	106	treatment
O	107	110	for
O	111	117	breast
O	118	124	cancer
O	124	125	.

O	126	133	Obesity
O	134	136	is
O	137	147	associated
O	148	152	with
O	153	157	poor
O	158	167	prognosis
O	168	171	and
O	172	176	risk
O	177	179	of
O	180	189	treatment
O	190	194	side
O	194	195	-
O	195	202	effects
O	203	205	in
O	206	212	breast
O	213	219	cancer
O	220	229	survivors
O	229	230	.

O	231	235	This
O	236	241	pilot
O	242	247	study
O	248	256	assessed
O	257	260	the
O	261	272	feasibility
O	272	273	,
O	274	287	acceptability
O	287	288	,
O	289	295	safety
O	296	299	and
O	300	308	efficacy
O	309	311	of
O	312	313	a
O	314	323	telephone
O	323	324	-
O	324	333	delivered
O	334	340	weight
O	341	345	loss
O	346	358	intervention
O	358	359	,
B-eligibility	360	365	among
I-eligibility	366	371	women
I-eligibility	372	373	(
I-eligibility	373	376	BMI
I-eligibility	377	379	25
I-eligibility	379	380	-
I-eligibility	380	382	40
I-eligibility	383	385	kg
I-eligibility	385	386	/
I-eligibility	386	388	m2
I-eligibility	389	390	)
I-eligibility	391	400	following
I-eligibility	401	410	treatment
I-eligibility	411	414	for
I-eligibility	415	420	stage
I-eligibility	421	422	I
I-eligibility	422	423	-
I-eligibility	423	426	III
I-eligibility	427	433	breast
I-eligibility	434	440	cancer
O	440	441	,
O	442	444	on
B-outcome-Measure	445	451	weight
I-outcome-Measure	452	456	loss
O	457	458	(
O	458	465	primary
O	466	473	outcome
O	473	474	)
O	474	475	,
B-outcome-Measure	476	483	quality
I-outcome-Measure	484	486	of
I-outcome-Measure	487	491	life
O	492	495	and
B-outcome-Measure	496	505	treatment
I-outcome-Measure	505	506	-
I-outcome-Measure	506	513	related
I-outcome-Measure	514	518	side
I-outcome-Measure	518	519	-
I-outcome-Measure	519	526	effects
O	527	528	(
O	528	530	vs
B-control	531	536	usual
I-control	537	541	care
O	541	542	)
O	542	543	.

B-total-participants	544	550	Ninety
O	551	556	women
O	557	558	(
O	558	562	mean
O	563	564	±
O	565	567	SD
O	568	571	age
O	571	572	:
B-age	573	575	55
I-age	575	576	.
I-age	576	577	3
I-age	578	579	±
I-age	580	581	8
I-age	581	582	.
I-age	582	588	7years
O	588	589	;
O	590	593	BMI
O	593	594	:
O	595	597	31
O	597	598	.
O	598	599	0
O	600	601	±
O	602	603	4
O	603	604	.
O	604	605	3
O	606	608	kg
O	608	609	/
O	609	611	m2
O	612	613	;
O	614	616	15
O	616	617	.
O	617	618	9
O	619	620	±
O	621	622	2
O	622	623	.
O	623	624	9
O	625	631	months
O	632	645	postdiagnosis
O	645	646	)
O	646	647	,
O	648	657	recruited
O	658	662	from
O	663	664	a
O	665	670	state
O	670	671	-
O	671	676	based
O	677	683	cancer
O	684	692	registry
O	692	693	,
O	694	698	were
O	699	709	randomized
O	710	712	to
O	713	714	a
O	715	721	weight
O	722	726	loss
O	727	728	(
O	728	732	diet
O	733	736	and
O	737	745	physical
O	746	754	activity
O	754	755	)
O	756	768	intervention
O	769	770	(
O	770	771	n
O	772	773	=
B-intervention-participants	774	776	45
O	776	777	)
O	778	780	or
O	781	786	usual
O	787	791	care
O	792	793	(
O	793	794	n
O	795	796	=
B-control-participants	797	799	45
O	799	800	)
O	800	801	.

O	802	806	Data
O	807	816	collected
O	817	819	at
O	820	828	baseline
O	829	832	and
O	833	834	6
O	835	841	months
O	842	850	included
O	851	857	weight
O	857	858	,
O	859	863	body
O	864	875	composition
O	875	876	,
O	877	884	quality
O	885	887	of
O	888	892	life
O	892	893	,
O	894	901	fatigue
O	902	905	and
O	906	910	body
O	911	916	image
O	916	917	.

O	918	931	Acceptability
O	932	935	and
O	936	948	satisfaction
O	949	953	were
O	954	962	assessed
O	963	965	in
O	966	978	intervention
O	979	991	participants
O	991	992	.

O	993	1004	Oncologists
O	1005	1013	provided
O	1014	1021	consent
O	1022	1024	to
O	1025	1032	contact
O	1033	1035	82
O	1035	1036	.
O	1036	1037	6
O	1037	1038	%
O	1039	1041	of
O	1042	1050	patients
O	1050	1051	,
O	1052	1056	with
O	1057	1059	84
O	1059	1060	.
O	1060	1061	1
O	1061	1062	%
O	1063	1065	of
O	1066	1071	those
O	1072	1077	women
O	1078	1087	contacted
O	1088	1091	and
O	1092	1100	eligible
O	1101	1111	consenting
O	1112	1114	to
O	1115	1126	participate
O	1126	1127	.

O	1128	1136	Compared
O	1137	1141	with
O	1142	1147	usual
O	1148	1152	care
O	1152	1153	,
B-outcome	1154	1158	mean
I-outcome	1159	1165	weight
I-outcome	1166	1170	loss
O	1171	1174	was
O	1175	1188	significantly
O	1189	1196	greater
O	1197	1199	in
O	1200	1203	the
O	1204	1216	intervention
O	1217	1220	arm
O	1221	1222	(
B-iv-cont-mean	1222	1223	-
I-iv-cont-mean	1223	1224	3
I-iv-cont-mean	1224	1225	.
I-iv-cont-mean	1225	1226	1
I-iv-cont-mean	1227	1229	kg
O	1230	1231	[
O	1231	1233	95
O	1233	1234	%
O	1235	1237	CI
O	1237	1238	,
O	1239	1240	-
O	1240	1241	5
O	1241	1242	.
O	1242	1243	4
O	1244	1246	to
O	1247	1248	-
O	1248	1249	0
O	1249	1250	.
O	1250	1251	7
O	1251	1252	]
O	1252	1253	;
O	1254	1255	-
O	1255	1256	3
O	1256	1257	.
O	1257	1258	7
O	1258	1259	%
O	1260	1268	baseline
O	1269	1275	weight
O	1276	1277	[
O	1277	1279	95
O	1279	1280	%
O	1281	1283	CI
O	1283	1284	,
O	1285	1286	-
O	1286	1287	6
O	1287	1288	.
O	1288	1289	6
O	1290	1292	to
O	1293	1294	-
O	1294	1295	0
O	1295	1296	.
O	1296	1297	9
O	1297	1298	]
O	1298	1299	)
O	1299	1300	,
O	1301	1303	as
O	1304	1308	were
B-outcome	1309	1319	reductions
I-outcome	1320	1322	in
I-outcome	1323	1326	fat
I-outcome	1327	1331	mass
O	1332	1333	(
B-iv-cont-mean	1333	1334	-
I-iv-cont-mean	1334	1335	2
I-iv-cont-mean	1335	1336	.
I-iv-cont-mean	1336	1337	1
I-iv-cont-mean	1338	1340	kg
O	1341	1342	[
O	1342	1344	95
O	1344	1345	%
O	1346	1348	CI
O	1348	1349	,
O	1350	1351	-
O	1351	1352	4
O	1352	1353	.
O	1353	1354	2
O	1355	1357	to
O	1358	1359	-
O	1359	1360	0
O	1360	1361	.
O	1361	1362	1
O	1362	1363	]
O	1363	1364	)
O	1365	1368	and
B-outcome	1369	1374	waist
I-outcome	1375	1388	circumference
O	1389	1390	(
B-iv-cont-mean	1390	1391	-
I-iv-cont-mean	1391	1392	4
I-iv-cont-mean	1392	1393	.
I-iv-cont-mean	1393	1394	0
I-iv-cont-mean	1395	1397	cm
O	1398	1399	[
O	1399	1401	95
O	1401	1402	%
O	1403	1405	CI
O	1405	1406	,
O	1407	1408	-
O	1408	1409	6
O	1409	1410	.
O	1410	1411	6
O	1412	1414	to
O	1415	1416	-
O	1416	1417	1
O	1417	1418	.
O	1418	1419	3
O	1419	1420	]
O	1420	1421	)
O	1421	1422	.

O	1423	1425	No
O	1426	1431	other
O	1432	1445	statistically
O	1446	1457	significant
O	1458	1470	intervention
O	1471	1478	effects
O	1479	1483	were
O	1484	1492	observed
O	1492	1493	.

O	1494	1506	Participants
O	1507	1511	were
O	1512	1518	highly
B-outcome	1519	1528	satisfied
O	1529	1533	with
O	1534	1537	the
O	1538	1550	intervention
O	1551	1558	overall
O	1559	1562	and
O	1563	1565	it
O	1566	1568	is
O	1569	1575	timing
O	1576	1578	in
O	1579	1587	relation
O	1588	1590	to
O	1591	1600	diagnosis
O	1600	1601	/
O	1601	1610	treatment
O	1610	1611	.

O	1612	1615	One
O	1616	1624	reported
B-outcome	1625	1632	adverse
I-outcome	1633	1638	event
I-outcome	1639	1640	(
I-outcome	1640	1655	musculoskeletal
I-outcome	1656	1662	injury
I-outcome	1662	1663	)
O	1664	1667	was
O	1668	1680	attributable
O	1681	1683	to
O	1684	1687	the
O	1688	1700	intervention
O	1700	1701	.

O	1702	1706	This
O	1707	1713	weight
O	1714	1718	loss
O	1719	1731	intervention
O	1732	1735	was
B-outcome	1736	1744	feasible
O	1744	1745	,
B-outcome	1746	1756	acceptable
O	1756	1757	,
B-outcome	1758	1762	safe
O	1763	1766	and
B-outcome	1767	1776	effective
O	1777	1780	for
O	1781	1786	women
O	1787	1788	1
O	1788	1789	-
O	1789	1790	2
O	1791	1796	years
O	1797	1802	after
O	1803	1804	a
O	1805	1811	breast
O	1812	1818	cancer
O	1819	1828	diagnosis
O	1828	1829	.

O	1830	1833	The
O	1834	1840	effect
O	1841	1843	of
O	1844	1850	weight
O	1851	1855	loss
O	1856	1858	on
O	1859	1866	quality
O	1867	1869	of
O	1870	1874	life
O	1875	1878	and
O	1879	1888	treatment
O	1888	1889	-
O	1889	1896	related
O	1897	1901	side
O	1901	1902	-
O	1902	1909	effects
O	1910	1916	should
O	1917	1919	be
O	1920	1928	examined
O	1929	1936	further
O	1937	1939	in
O	1940	1945	fully
O	1945	1946	-
O	1946	1953	powered
O	1954	1961	studies
O	1961	1962	.
